Nurosene's NetraAI technology was successful in self-generating hypotheses from proprietary data sets that will accelerate clinical trials and help build Nurosene's IP portfolio.
Nurosene Health Inc.( $MEND.C $MNNDF) had some big news today announcing they have released preliminary findings from an age-related data set that was derived from skin samples of young and elderly people.
These findings will enable significantly increased efficiency in the development of anti-ageing therapeutics because $MEND NetraAI tech was able to find several meaningful and novel biological mechanisms that are believed to be at play in ageing.
These findings will enhance $MEND's current longevity study.
These results will be used to expand $MEND's IP portfolio and will also serve to attract partnerships with pharmaceutical and biotech companies.
Despite this great news, $MEND is down about 13%, so it might be a good time to jump in.
$MEND @ 1.63
https://ca.finance.yahoo.com/news/nurosene-releases-preliminary-findings-support-143000347.html